ClinicalTrials.gg
CompletedNCT00510510Updated May 21, 2012Results posted

Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

A Phase 2 interventional study of NVA237 100 µg and Placebo in Chronic Obstructive Pulmonary Disease (COPD), sponsored by Novartis. Completed at 21 sites in 6 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2012-05-21.

Sponsored by Novartis · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
281
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.

Enrollment
30th of 73
281 · median 152
Started
2007
with 3 others
Phase 2
19 of 73
none open now
Registered
3rd of 73
by date
Lead sponsor
6 of 73
Novartis

Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 30th largest by enrollment, is one of 4 that started in 2007, is one of 19 in phase 2, and was the 3rd registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About glycopyrrolate

Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This study assessed the safety/tolerability of 28 days of treatment with NVA237 100 µg and 200 µg once a day, compared to placebo in patients with moderate or severe Chronic Obstructive Pulmonary Disease (COPD).

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)

Keywords

  • COPD
  • glycopyrronium bromide
  • antimuscarinic
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female adults aged 40 years or older
  • Patients with moderate to severe according to the GOLD Guidelines (2006)
  • Patients who have smoking history of at least 10 pack years
  • Patients with a post-bronchodilator (FEV1) equal or greater than 30% of the predicted normal value and less than 80% of the predicted normal value, and post-bronchodilator FEV1/FVC less than 0.7 at visit 2
  • Written by the patient prior to initiation of any study-related procedure

Exclusion criteria

Exclusion Criteria:

  • Patients requiring oxygen therapy on a daily basis for chronic hypoxemia, or who have been hospitalized for an exacerbation of their airways disease in the 6 weeks prior to visit 1 or during the screening period (up to visit 3).
  • Patients who have had a respiratory tract infection within 6 weeks prior to visit 1 or during the screening period (up to visit 3).
  • Patients with a history of asthma indicated by (but not limited to):

Blood eosinophil count > 400/mm3, onset of symptoms prior to age 40 years.

  • Patients with a history of long syndrome or whose QTc measured at visit 1 is prolonged (more than 440 ms for males or more than 460 ms for females).
  • Patients with a history of untoward reactions to sympathomimetic amines or inhaled medication or any component thereof.
  • Patients who, in the judgment of the investigator have a laboratory abnormality or a clinically significant condition such as (but not limited to) unstable ischemic heart disease, left ventricular failure, long term prednisone therapy, history of myocardial infarction, arrhythmia, narrow-angle glaucoma, symptomatic prostatic hyperplasia, bladder-neck obstruction or moderate to severe renal impairment that might compromise patient safety or compliance, interfere with evaluation, or preclude completion of the study.
  • History of of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or , with the exception of localized basal cell carcinoma of the skin.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
281 participants (actual)

Study arms

  • Experimental
    NVA237 100 µg

    Drug: NVA237 100 µg

  • Experimental
    NVA237 200 µg

    Drug: NVA237 200 µg

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Dry powder inhalation once a day for up to 28 days

    Also known as: Glycopyrronium Bromide

  • DrugPlacebo

    Placebo to NVA237 dry powder inhalation once a day for up to 28 days

  • Dry powder inhalation once a day for up to 28 days

    Also known as: Glycopyrronium Bromide

06

What researchers measure

Primary outcomes

  1. Safety of Treatment With NVA237 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

    The assessment of safety was based on adverse events, particularly those adverse events known to be associated to treatment with muscarinic antagonists. A summary of adverse events is presented with this outcome, additional details are provided in Adverse Events Sections.

    Time frame: 28 days

Secondary outcomes

  1. Least Squares Means of Trough Forced Expiratory Volume in One Second (FEV1), by Day

    Forced expiratory volume maneuvers recorded using a calibrated spirometer. Trough forced expiratory volume in one second (FEV1) on Days 1 \& 28 defined as the mean of the FEV1 values measured at 23 hours 15 minutes and 23 hours 45 minutes post-dose.

    Time frame: 28 Days

07

Results

Posted Jan 21, 2011

Participant flow

Participant flow — Overall Study
MilestoneNVA237 100 µgNVA237 200 µgPlacebo
Started929891
Completed878974
Not completed5917
Withdrew: Adverse event436
Withdrew: Lack of efficacy011
Withdrew: Subjects no longer requires study drug002
Withdrew: Withdrawal by subject123
Withdrew: Lost to follow-up001
Withdrew: Protocol violation034

Outcome measures

PrimarySafety of Treatment With NVA237 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

The assessment of safety was based on adverse events, particularly those adverse events known to be associated to treatment with muscarinic antagonists. A summary of adverse events is presented with this outcome, additional details are provided in Adverse Events Sections.

Time frame:
28 days
Reported as:
Number · Participants
Safety of Treatment With NVA237 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
ParticipantsNVA237 100 µgNVA237 200 µgPlacebo
Total number of patients with any AE262624
Total number with any significant AE346
SecondaryLeast Squares Means of Trough Forced Expiratory Volume in One Second (FEV1), by Day

Forced expiratory volume maneuvers recorded using a calibrated spirometer. Trough forced expiratory volume in one second (FEV1) on Days 1 \& 28 defined as the mean of the FEV1 values measured at 23 hours 15 minutes and 23 hours 45 minutes post-dose.

Time frame:
28 Days
Reported as:
Least squares mean · Liters
Least Squares Means of Trough Forced Expiratory Volume in One Second (FEV1), by Day
LitersNVA237 100 µgNVA237 200 µgPlacebo
Trough FEV1 Day 11.465 ± 0.01521.480 ± 0.01491.334 ± 0.0154
Trough FEV1 Day 281.502 ± 0.01821.492 ± 0.01801.341 ± 0.0200

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NVA237 100 µg—0/92 (0%)7/92 (7.6%)
NVA237 200 µg—1/98 (1%)10/98 (10.2%)
Placebo—1/91 (1.1%)4/91 (4.4%)
Most frequent serious events
Most frequent serious events
EventNVA237 100 µgNVA237 200 µgPlacebo
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/920/981/91
PneumoniaInfections and infestations0/921/980/91
Most frequent other events
Most frequent other events
EventNVA237 100 µgNVA237 200 µgPlacebo
Dry mouthGastrointestinal disorders3/927/980/91
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders5/923/984/91

Baseline characteristics

Age Continuous
Age Continuous(years)NVA237 100 µgNVA237 200 µgPlaceboTotal
Mean64.2 ± 7.9362.6 ± 9.0463.4 ± 9.4463.4 ± 8.82
Sex: Female, Male
Sex: Female, Male(Participants)NVA237 100 µgNVA237 200 µgPlaceboTotal
Female35292791
Male576964190
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)NVA237 100 µgNVA237 200 µgPlaceboTotal
Hispanic or Latino17151143
Not Hispanic or Latino727976227
Unknown or Not Reported34411
Race (NIH/OMB)
Race (NIH/OMB)(Participants)NVA237 100 µgNVA237 200 µgPlaceboTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0101
Black or African American0336
White909488272
More than one race0000
Unknown or Not Reported2002
08

Study locations

21 sites
  • Novartis investigative site
    Glendale, Arizona 85306, United States
  • Novartis investigative site
    Phoenix, Arizona 85006, United States
  • Novartis investigative site
    Wheat Ridge, Colorado 80033, United States
  • Novartis investigative site
    Newark, Delaware 19713, United States
  • Novartis investigative site
    Miami, Florida 33143, United States
  • Novartis investigative site
    Miami, Florida 33169, United States
  • Novartis investigative site
    Tamarac, Florida 33321, United States
  • Novartis investigative site
    River Forest, Illinois 60305, United States
  • Novartis investigative site
    Overland Park, Kansas 66210-2761, United States
  • Novartis investigative site
    St. Chares, Missouri 63301, United States
  • Novartis investigative site
    Charlotte, North Carolina 28207, United States
  • Novartis investigative site
    Portland, Oregon 97213, United States
  • Novartis investigative site
    Spartanburg, South Carolina 29303, United States
  • Novartis investigative site
    Union, South Carolina 29379, United States
  • Novartis investigative site
    Ft Worth, Texas 76104, United States
  • Novartis investigative site
    Houston, Texas 77024, United States
  • Novartis investigative site
    Rueil-Malmaison, France
  • Novartis investigative site
    Nurnberg, Germany
  • Novartis investigative site
    Arnhem, Netherlands
  • Novartis investigative site
    Barcelona, Spain
  • Novartis investigative site
    Istanbul, Turkey
09

References and documents

Publications

  • Vogelmeier C, Verkindre C, Cheung D, Galdiz JB, Guclu SZ, Spangenthal S, Overend T, Henley M, Mizutani G, Zeldin RK. Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Pulm Pharmacol Ther. 2010 Oct;23(5):438-44. doi: 10.1016/j.pupt.2010.04.005. Epub 2010 Apr 21. PubMed 20416390 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2007, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2011, 3 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2007
First posted
Aug 2, 2007
Start
Aug 2007
Primary completionActual
Jan 2008
CompletionActual
Jan 2008
Results first posted
Jan 21, 2011
Last update
May 21, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00510510
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Aug 2, 2007
Start date
Aug 2007
Primary completion
Jan 2008
Completion
Jan 2008
Results posted
Jan 21, 2011
Last update
May 21, 2012

Study contacts

Novartis Pharmaceuticals
study chair · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glycopyrrolate

Start the discussion